Phase II Study for Patients With Advanced Triple Negative or Metaplastic HR-positive/HER2-negative, PIK3CA/PTEN-altered Breast Cancer Treated With Eribulin in Combination With MEN1611
Latest Information Update: 27 Apr 2025
At a glance
- Drugs MEN 1611 (Primary) ; Eribulin
- Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer
- Focus First in man; Therapeutic Use
- Acronyms SABINA
Most Recent Events
- 20 Dec 2024 Planned number of patients changed from 28 to 14.
- 26 May 2023 Status changed from not yet recruiting to recruiting.
- 14 Apr 2023 New trial record